Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes

Table 2 Assessment of treatments for efficacy in glycemic control in the 2 groups

Variables	0 week	12 weeks	24 weeks
HbA1c (%)
The group A	9.3 ± 1.5	8.2 ± 1.2*	7.3 ± 1.3**
The group B	9.4 ± 1.4	8.6 ± 1.3*	7.9 ± 1.3*^#
FBG (mmol/L)
The group A	11.4 ± 2.4	7.6 ± 1.8**	6.9 ± 1.3**
The group B	11.3 ± 2.6	8.2 ± 2.1**	7.7 ± 1.6**^#
P2BG (mmol/L)
The group A	16.8 ± 4.4	11.2 ± 2.3**	8.6 ± 2.1**
The group B	17.0 ± 4.5	12.4 ± 2.3**	10.8 ± 2.2**^#
Insulin dose (unit/day)
The group A	68.6 ± 14.6	44.8 ± 15.9**	32.3 ± 14.9**
The group B	66.8 ± 13.9	79.3 ± 14.8*	86.2 ± 18.9**^#^#
Body Weight (kg)
The group A	66.2 ± 16.3	66.4 ± 16.5	66.9 ± 16.6
The group B	67.2 ± 15.9	68.3 ± 16.0	69.8 ± 16.5**^#

Data expressed mean ± SD; HbA1c: Glycosylated hemoglobin; FBG: fasting blood glucose; P2BG: 2-hour postprandial blood glucose; *p < 0.05 vs. baseline, **p < 0.01 vs. baseline. ^#p < 0.05 group A vs. group B, ^##p < 0.01 group A vs. group B.

ISSN: 1758-5996